Last reviewed · How we verify
DA-5213 10mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
DA-5213 10mg (DA-5213 10mg) — Dong-A ST Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DA-5213 10mg TARGET | DA-5213 10mg | Dong-A ST Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DA-5213 10mg CI watch — RSS
- DA-5213 10mg CI watch — Atom
- DA-5213 10mg CI watch — JSON
- DA-5213 10mg alone — RSS
Cite this brief
Drug Landscape (2026). DA-5213 10mg — Competitive Intelligence Brief. https://druglandscape.com/ci/da-5213-10mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing